The Second Clinical Medical College, Zhejiang Chinese Medical University, 310053, Hangzhou, China; Department of Radiology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, 310013, Hangzhou, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
Clin Radiol. 2020 Jun;75(6):478.e1-478.e11. doi: 10.1016/j.crad.2019.12.023. Epub 2020 Feb 6.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumours. PDAC has a poor prognosis; therefore, it is necessary to perform further risk stratification. Identifying prognostic factors before treatment might help to implement suitable and personalised treatment for individuals and avoid side effects. Conventional staging systems and tumour biomarkers are fundamental to establish prognosis; however, they have obvious limitations. Novel imaging biomarkers extracted from advanced imaging techniques offer opportunities to evaluate underlying tumour physiological characteristics, such as mutational status, cellular composition, local microenvironment, tumour metabolism, and biological behaviour. Thus, imaging biomarkers might help the decision making of oncologists and surgeons. The present review discusses the functions of imaging biomarkers for prognostic prediction in patients with PDAC and their potential value for further translation in clinical practice.
胰腺导管腺癌（PDAC）是最具侵袭性的肿瘤之一。PDAC 的预后较差；因此，有必要进行进一步的风险分层。在治疗前识别预后因素可能有助于为个体实施合适和个性化的治疗，并避免副作用。传统的分期系统和肿瘤标志物是确定预后的基础；然而，它们有明显的局限性。从先进的成像技术中提取的新型成像生物标志物为评估潜在的肿瘤生理特征提供了机会，例如突变状态、细胞组成、局部微环境、肿瘤代谢和生物学行为。因此，成像生物标志物可能有助于肿瘤学家和外科医生做出决策。本综述讨论了成像生物标志物在 PDAC 患者预后预测中的作用及其在临床实践中进一步转化的潜在价值。
